Oral Orforglipron Holds 75–79% of Prior Weight Loss

A Phase 3b trial published May 12 in Nature Medicine found that people who switched from injectable GLP-1 drugs to Eli Lilly's oral orforglipron (Foundayo) maintained the majority of their prior weight loss over 52 weeks — a clinically meaningful result that addresses one of the most common real-world questions in GLP-1 prescribing: what happens when someone wants to stop injecting?

What Happened

The ATTAIN-MAINTAIN trial enrolled patients who had already completed 72 weeks of treatment with either semaglutide (Wegovy) or tirzepatide (Zepbound) as part of prior Phase 3 studies, achieving substantial weight reduction. Those participants were then randomized to continue with either once-daily oral orforglipron or placebo for an additional 52 weeks.

Results at one year:

• Patients who had been on tirzepatide and switched to orforglipron maintained a mean 74.7% of their earlier body weight reduction, versus 49.2% in the placebo group
• Patients who had been on semaglutide and switched to orforglipron maintained a mean 79.3% of their earlier reduction

The weight maintenance benefit extended to secondary endpoints including waist circumference, blood pressure, blood sugar, triglycerides, and cholesterol — all of which deteriorated more in the placebo group than in the orforglipron group.

Safety data were consistent with orforglipron's profile in prior Phase 3 studies: predominantly mild-to-moderate GI side effects (nausea, diarrhea) with no new safety signals identified.

Why It Matters

This trial answers a question that didn't exist two years ago: now that an approved oral GLP-1 (Foundayo, approved April 1, 2026) exists, is it a viable transition for patients who respond to injectable therapy but want to stop weekly injections?

ATTAIN-MAINTAIN is the first Phase 3 evidence that the answer is yes, with a meaningful caveat: "maintenance" at 75–79% of prior loss is not the same as continuing on the injectable. The placebo group still maintained roughly half their prior weight reduction (49%) over the year, which reflects both the durability of some behavioral changes and the difficulty of fully attributing weight regain to drug withdrawal.

The gap between orforglipron and placebo — roughly 25–30 percentage points of maintained weight reduction — is the meaningful signal. For patients who plateaued on an injectable and are happy with their current weight, transitioning to orforglipron appears to preserve most of those results.

This also raises the question of step-down strategy: for patients on tirzepatide who achieve significant weight loss and then step down to oral semaglutide or orforglipron for maintenance, the data now exist to inform that conversation.

What to Watch

Eli Lilly has multiple orforglipron studies underway. The ACHIEVE trials are evaluating the drug for type 2 diabetes, and the company has indicated it expects to file for expanded indications through 2026. ATTAIN-MAINTAIN will likely become a reference trial for payer coverage decisions around oral GLP-1 maintenance prescribing — an area where coverage criteria are still being written.

For patients on Foundayo already, this trial is indirect reassurance that the drug's mechanism is real and the weight maintenance effect is clinically meaningful.

Sources

• ATTAIN-MAINTAIN trial, Nature Medicine (May 12, 2026)
• Eli Lilly press release
• Patient Care Online coverage